Dengue Virus Type II Antibody, clone 3H5-1 | EMD Millipore MAB8702 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

EMD Millipore

other brands :

Oncogene Research Products, Calbiochem, Novagen, Merck, Upstate Biotechnology, Chemicon, LINCO, Novabiochem, Guava

product type :

antibody

product name :

Dengue Virus Type II Antibody, clone 3H5-1

catalog :

MAB8702

quantity :

100 μg

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

3H5-1

reactivity :

Dengue virus, Dengue virus 2, human

application :

immunohistochemistry, immunocytochemistry, immunoprecipitation

citations: 10

Published Application/Species/Sample/Dilution	Reference
immunocytochemistry; human; loading ...; fig 5b	Barbier V, Lang D, Valois S, Rothman A, Medin C. Dengue virus induces mitochondrial elongation through impairment of Drp1-triggered mitochondrial fission. Virology. 2017;500:149-160 pubmed publisher
immunoprecipitation; Dengue virus	Conway M, Londono Renteria B, Troupin A, Watson A, Klimstra W, Fikrig E, et al. Aedes aegypti D7 Saliva Protein Inhibits Dengue Virus Infection. PLoS Negl Trop Dis. 2016;10:e0004941 pubmed publisher
immunohistochemistry; Dengue virus 2; 1:300; fig f3	Cime Castillo J, Delannoy P, Mendoza HernÃ¡ndez G, Monroy MartÃnez V, Harduin Lepers A, Lanz Mendoza H, et al. Sialic acid expression in the mosquito Aedes aegypti and its possible role in dengue virus-vector interactions. Biomed Res Int. 2015;2015:504187 pubmed publisher
immunocytochemistry; Dengue virus; 1:200	Conway M, Watson A, Colpitts T, Dragovic S, Li Z, Wang P, et al. Mosquito saliva serine protease enhances dissemination of dengue virus into the mammalian host. J Virol. 2014;88:164-75 pubmed publisher
immunoprecipitation; human immunocytochemistry; human	de Wispelaere M, Yang P. Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly. J Virol. 2012;86:7072-83 pubmed publisher
	Fontaine K, Sanchez E, Camarda R, Lagunoff M. Dengue virus induces and requires glycolysis for optimal replication. J Virol. 2015;89:2358-66 pubmed publisher
	Zhang Z, Weng Y, Huang H, Zhang J, Yan Y. Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen. Mol Med Rep. 2015;11:1009-16 pubmed publisher
	De Burghgraeve T, Kaptein S, Ayala Nuñez N, Mondotte J, Pastorino B, Printsevskaya S, et al. An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro. PLoS ONE. 2012;7:e37244 pubmed publisher
	van der Schaar H, Rust M, Chen C, van der Ende Metselaar H, Wilschut J, Zhuang X, et al. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog. 2008;4:e1000244 pubmed publisher
	van der Schaar H, Rust M, Waarts B, van der Ende Metselaar H, Kuhn R, Wilschut J, et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol. 2007;81:12019-28 pubmed

product information

Catalog Number :

MAB8702

Subcategory :

Infectious Diseases

Product Name :

Anti-Dengue Virus Type II Antibody, clone 3H5-1

Product Type :

Antibodies

Clonality :

Monoclonal Antibody

Host Name :

Mouse

Antigen :

Dengue Virus Type II

Clone :

3H5-1

Conjugate :

Purified

Isotype :

IgG1

Product Description :

Anti-Dengue Virus Type II Antibody, clone 3H5-1

Cross Reactivity :

Human

Background :

Dengue fever is an acute, mosquito-transmitted viral disease characterized by fever, headache, arthralgia (severe retro-orbital pain), myalgia, rash, nausea, and vomiting. Infections are caused by any of the four closely related, but antigenically distinct virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross-protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. Dengue is primarily an urban disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Although most dengue infections result in relatively mild illness, some can produce Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome, with children being particularly at risk. Although epidemic outbreaks have been reported since 1779, the incidence has been increasing, with global, multiple serotype pandemics intensifying within the last 15 years. There is no specific antiviral therapy for dengue, but for both classical dengue and dengue hemorrhagic fever, symptomatic and supportive measures are effective. Important risk factors for DHF include the strain and serotype of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.

Immunogen :

Dengue type 2 antigen (New Guinea C).

Specificity :

Reacts with the Dengue type 2 virus.

Package Size :

100 μg

Uses :

Hemagglutination Inhibition;Immunofluorescence

Storage :

Maintain at 2°C to 8°C in undiluted aliquots for up to 12 months after date of receipt.